Date: 2013-07-04
Type of information: R&D agreement
Compound: bioinformatics services
Company: Debiopharm (Switzerland) Quartz Bio (Switzerland)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On July 4, 2013, Debiopharm, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, has announced the signing of a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery. Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery. Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.
Quartz Bio SA is a clinical bioinformatics service company specialized in exploratory biomarker data analyses for the generation of precision medicine hypotheses. The company has been created in september 2012 and Quartz Bio is the second spin-off company resulting from Merck Serono\'s Entrepreneur Partnership Program launched in April 2012. Quartz Bio provides modular data analysis solutions to the major steps of the biomarker development process. These include: biomarker study design, biomarker data quality control, statistical analysis and scientific reporting. The capital of the company is entirely owned by its employees, who are scientists from diverse educational backgrounds with a common track record of 6 to 10 years clinical bioinformatics experience in the pharmaceutical sector. Quartz Bio is headed by Jérôme Wojcik, a seasoned expert in bioinformatics.
Financial terms:
Latest news:
